

ASX Announcement

Medibio Limited – 5 June 2017



Medibio Limited Begins Trading on OTCQB Under Ticker Symbol MDBIF

Sydney, Australia – 5 June 2017: Medibio Limited (ASX:MEB) (OTCQB: MDBIF) announced today that its common stock will begin trading on the OTC Market Group’s OTCQB® Venture Market under the ticker symbol “MDBIF” effective June 5, 2017.

OTCQB is designed for early-stage and developing U.S. and international companies that are current in their reporting and undergo an annual verification and management certification process. The OTCQB® Venture Market is considered by the SEC as an “established public market” for the purpose of determining the public market price when registering securities for resale in equity line financings with the SEC.

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF), is an evidence-based medical technology company that has developed an objective test to assist in the diagnosis and management of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (and patent pending) panel circadian, sleep and autonomic system biomarkers to objectively quantify and characterize mental illness. Medibio’s depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio’s application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio’s technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology and App market. Located in Melbourne (Vic) Medibio is listed on the Australian Securities Exchange Ltd. Medibio (OTCQB: MDBIF) trades on the OTCQB Venture Market for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com.

– ENDS –

Further Information: Website: www.medibio.com.au	
U.S. Media Enquiries to: Nancy Thompson Vorticom Inc. nancyt@vorticom.com T: + 1 (212) 532 2208	Australian Media Enquiries: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0)412 036 231